Erlotinib Hydrochloride

• 

  Subject Areas on Research

  • A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). 
  • A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. 
  • Adjuvant chemotherapy for non-small cell lung cancer. 
  • An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. 
  • Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. 
  • CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. 
  • Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. 
  • Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. 
  • Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts. 
  • Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy. 
  • Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. 
  • Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? 
  • Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. 
  • Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. 
  • EGF promotes mammalian cell growth by suppressing cellular senescence. 
  • EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. 
  • Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs. 
  • Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. 
  • Epidermal growth factor regulates hematopoietic regeneration after radiation injury. 
  • Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. 
  • Gefitinib for refractory advanced non-small-cell lung cancer. 
  • Glioblastoma multiforme and the epidermal growth factor receptor. 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. 
  • Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. 
  • Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. 
  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. 
  • Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. 
  • Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. 
  • Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. 
  • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. 
  • Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. 
  • Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. 
  • Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. 
  • Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. 
  • Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. 
  • Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 
  • Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. 
  • Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. 
  • SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. 
  • Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. 
  • TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway. 
  • Targeted therapies for cancer 2004. 
  • Targeted therapy in rectal cancer. 
  • Targeting the future in head and neck cancer. 
  • The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. 
  • The past, present, and future management of brain metastases in EGFR-mutant non-small cell lung cancer. 
  • The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.